VANCOUVER, October 26, 2010 /PRNewswire/ -- Sirius Genomics, a developer of companion diagnostics, announced today that U.S. Patent No. 7,820,376 entitled Protein C Polymorphisms has been issued by the United States Patent and Trademark Office. The patent relates to a novel use of a Single Nucleotide Polymorphism (SNP) located in the Protein C gene.
The patent covers methods of predicting outcome or prognosis in sepsis, and other related conditions, by determining a subject's genotype at the SNP. This patent issuance further strengthens Sirius' patent portfolio and position as a developer of companion diagnostics, stated Dr. Jennifer Kaufman-Shaw, Vice President, Intellectual Property at Sirius Genomics.
Sirius Genomics' steadily expanding patent estate stems from discoveries made from the Company's focused approach in the identification and validation of genetic markers linked to drug response. Our focus is on improving outcomes for patients treated with various classes of drugs used in the acute care setting, stated Chris Wagner, President and CEO of Sirius Genomics.
Sirius' intellectual property portfolio includes patent families related to several therapies available and under development for sepsis and other acute conditions.
About Sirius Genomics: http://www.siriusgenomics.com
Sirius Genomics develops companion diagnostics (CDx) that are closely tied to therapeutic decisions, leading to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The Company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable CDx products that enable better drug treatment. The Company's first product is a genetic predictor of response to treatment for sepsis, a severe blood infection. Learn more at http://www.siriusgenomics.com.
This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.
For further information: Chris Wagner President and CEO Sirius Genomics +1-604-484-7195
SOURCE: Sirius Genomics Inc.
CONTACT: For further information: Chris Wagner, President and CEO, SiriusGenomics, +1-604-484-7195